Corporate Banner
Satellite Banner
Technology Networks Header
Sunday, September 21, 2014
Technology Networks
 
Register | Sign in
Home Page > Latest Webcasts
  Webcasts
Scientific News
Novel Drug Targeting Leukemia Cells Enters Clinical Trial
Phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for CLL patients.
Researchers Discover What Lies Behind the Death of Stem Cells
Researchers have identified key processes that control stem cell survival, providing insights that could improve their use in medicine.
Genetic Testing for Prostate Cancer
Genetic testing can identify men at six-fold increased risk of prostate cancer.
Redefining High Risk Patients With Stage II Colon Cancer
microRNA-21 identified as an independent prognostic biomarker.
Leukemia Subtype Becomes More Common With Age
Genomic Analysis of 1,725 patients reveals the prevalence of Ph-like ALL increases with age.
Ovarian Cancer Oncogene Found in "Junk DNA"
The study is published online in this week in Cancer Cell.
New Genetic Target for a Different Kind of Cancer Drug
Upstream of the proteins that cancer cells use to proliferate sits RBM4, a gene-splicing protein that is drastically reduced in human lung and breast cancer cells.
Combination microRNA Therapy Suppresses Non-Small-Cell Lung Cancer
Findings offer a promising therapeutic avenue for NSCLC.
Breakthrough Melanoma Treatment, Keytruda, Developed
New immunotherapy launched in the US for treatment of adults with advanced melanoma, developed using antibody humanization expertise at UK’s MRC Technology.
New Gene Mutations for Wilms Tumor
UT Southwestern researchers identified the mutated genes by sequencing the DNA of 44 tumors.
Scroll Up
Scroll Down
Return
Developing Dicer-Substrate siRNA Drugs
Mark Behlke, Chief Scientific Officer, Integrated DNA Technologies, speaking at RNAi World Congress 2009
Date Posted: Friday, October 16, 2009
Print Page

For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here



IDT Acquires SURVEYOR® Nuclease Business from Transgenomic
Addition of SURVEYOR enzyme and kits expands IDT's molecular biology product offerings.
Wednesday, July 02, 2014
Providing a Rapid and Reliable Method of Gene Cloning
Integrated DNA Technologies will be speaking at the upcoming Antibody Engineering and Therapeutics conference.
Monday, December 02, 2013
Webinar: the Cutting-edge qPCR Approach to Single-cell Expression Profiling
Join IDT and Professor Mikael Kubista for insight into pioneering qPCR methods, June 25.
Monday, June 24, 2013
IDT Launches Michael Zuker’s UNAFold Page
UNAFold secondary structure prediction software to be used to accurately detect secondary structures within sequences submitted by customers.
Thursday, December 02, 2010
IDT Presents at Presidential Commission for the Study of Bioethical Issues
Representing the International Gene Synthesis Consortium and its ongoing work to prevent the misuse of synthetic genes.
Tuesday, September 21, 2010
IDT is Awarded Further Funding for Gene Silencing Research
Company receives a Phase II SIBR grant to fund the ongoing ‘Gene Silencing with U1 Adapter Oligonucleotides’ research project.
Thursday, July 22, 2010
IDT Earns ISO 9001:2008 Certification at its European Oligonucleotide Production Headquarters
Worldwide certification of quality systems at all manufacturing operations completed.
Tuesday, April 27, 2010
Integrated DNA Technologies and Glycon Partner in Australia
Glycon will offer Australia’s scientists local sales and technical support of IDT’s products, complementing IDT’s existing global customer care network.
Monday, April 19, 2010
IDT Secures Funding for new Gene Silencing Research
IDT has been awarded $99,750 from NIH to continue work on its ‘Gene Silencing with U1 Adapter Oligonucleotides’ research project.
Monday, September 07, 2009
Major International Conferences to Hear About the Risks and Rewards of Synthetic Biology
IDT will be presenting recent developments in RNAi research, at Analytica and the RNAi World Congress.
Wednesday, March 19, 2008
IDT Acquires Belgian Manufacturer RNA-TEC
Purchase expands IDT's large-scale RNA synthesis capabilities; builds presence in European markets.
Tuesday, September 19, 2006
 
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv